# US 8,772,267 B2 · Treatment of spinal mechanical pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,267 B2
- Document ID: US8772267B2
- Status: Granted
- Kind: B2
- Application number: 12/963,439
- Filed: 2010-12-08
- Published: 2011-04-28
- Granted: 2014-07-08
- Earliest claimed: 2002-07-24
- Assignees: New York University
- Applicants: Marco Pappagallo
- Inventors: Marco Pappagallo
- Web page: https://patentgrep.com/patent/US8772267B2

## CPC

- A61K 31/66: Phosphorus compounds
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.

## Claims

### Claim 1

A method of treating chronic spinal mechanical pain which comprises administering to a subject in need of chronic spinal mechanical pain relief an effective amount of a bisphosphonate that is effective for providing chronic spinal mechanical pain relief, wherein the bisphosphonate is an aminobisphosphonate.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chronic spinal mechanical pain is relieved for a prolonged period.

### Claim 3 (depends on 2)

The method of claim 2, wherein the prolonged period is more than one month following the administration of the bisphosphonate.

### Claim 4 (depends on 2)

The method of claim 2, wherein the prolonged period is at least three months following the administration of the bisphosphonate.

### Claim 5 (depends on 2)

The method of claim 2, wherein the prolonged period is at least six months following the administration of the bisphosphonate.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein the chronic spinal mechanical pain is of non-osteoporotic compression fracture origin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the chronic spinal mechanical pain is due to degenerative disc disease (DDD) and/or other mechanical causes.

### Claim 9 (depends on 1)

The method of claim 1, wherein the chronic spinal mechanical pain is associated with degenerative processes of the intervertebral spaces and/or facet joints.

### Claim 10 (depends on 1)

The method of claim 1, wherein the aminobisphosphonate is selected from the group consisting of alendronate, ibandronate, pamidronate, and zoledronic acid.

### Claim 11 (depends on 1)

The method of claim 1, wherein the effective amount of the bisphosphonate ranges from about 0.5 to about 5.4 mg/kg of body weight.

### Claim 12 (depends on 1)

The method of claim 1, wherein the effective amount of the bisphosphonate is at least 0.029 mg/kg of body weight.

### Claim 13 (depends on 1)

The method of claim 1 wherein the aminobisphosphonate is selected from the group consisting of alendronate, ibandronate, and pamidronate.